Clinical Trial Detail

NCT ID NCT04051606
Title Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

glioblastoma multiforme

gliosarcoma

malignant glioma

Therapies

Regorafenib

Age Groups: adult senior

No variant requirements are available.